Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer

Analysis of adverse drug reactions of Osimertinib in the 2nd‐line treatment of EGFR mutant advanced nonsmall cell lung cancer

Abstract The aim was to analyze the clinical characteristics of adverse drug reactions (ADRs) induced by Osimertinib and their effects on the prognosis, so as to further provide reference for clinical medication. This was a retrospective study, and 66 nonsmall cell lung cancer (NSCLC) patients who h...

Full description

Bibliographic Details
Main Authors: Yingying Jiang, Yue Shi, Zihan Wang, Hang Li, Zhitong Wang, Kang He, Yuxin Ma, Jingjing Xue, Yumeng Shi, Jianwei Lu, Meiqi Shi, Bo Shen, Guoren Zhou, Xiaohua Wang, Cheng Chen, Jifeng Feng
Format: Article
Language:English
Published: Wiley 2022-06-01
Series:Precision Medical Sciences
Subjects:
adverse drug reactions
nonsmall cell lung cancer
Osimertinib
Online Access:https://doi.org/10.1002/prm2.12075

Similar Items

Similar Items